Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas

We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular lymphomas. The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR). At a median follow-up of 18 month...

Full description

Bibliographic Details
Authors: Domingo Domènech, Eva, González Barca, Eva, Estany, Carla, Sureda, Anna, Besalduch, Joan, Fernández de Sevilla Ribosa, Alberto
Format: article
Status:Published version
Publication Date:2002
Country:España
Institution:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/172746
Online Access:https://hdl.handle.net/2445/172746
Access Level:Open access
Keyword:Anticossos monoclonals
Ús terapèutic
Limfomes
Monoclonal antibodies
Therapeutic use
Lymphomas
Description
Summary:We studied the safety and efficacy of combined treatment with rituximab plus CHOP in 16 patients with relapsed advanced-stage follicular lymphomas. The intent-to-treat overall response rate (ORR) was 88%, 75% complete remissions (CR) and 13% partial remissions (PR). At a median follow-up of 18 months, 63% of the patients are alive (50% CR). The combination of rituximab and CHOP in relapsed advanced-stage follicular lymphomas achieves high ORRs and CRs, with low toxicity except for in previously autografted patients.

Similar Items